Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. - Renaissance Capital Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up release that will more than double the tradable float. Cardiovascular disease biotech Braveheart Bio (BRVE) is set to raise $300 million at a $1.4 billion market cap. Immune system-focused biotech Attovia Therapeutics (ATTO) plans to raise $200 million at a $649 million market cap. Attovia is developing biologic therapies for immune-mediated diseases using its ATTOBODY platform to create next-generation antibody therapeutics targeting validated immune pathways. Its commercial real estate lending franchise accounted for roughly 90% of its loan portfolio as of June 30, 2026. River City has also developed a niche serving California Community Choice Aggregator entities, although the resulting deposit base is fairly concentrated. Metabolic disorder biotech Vogenx (VOGX) plans to raise $75 million at a $173 million market cap.

RANCHO CORDOVA, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases. The inaugural program under this partnership focuses on producing lentiviral vectors (LVV) to treat rare inherited blood and metabolic disorders. SK pharmteco has worked closely with NIH investigators to advance this effort. As part of that work, SK pharmteco manufactured drug substance intended for future ex vivo transduction of patients’ CD34+ hematopoietic stem cells and managed batch-release testing, with most analytical assays performed in-house at its specialized laboratories. “Axle is focused on connecting capabilities across the NIH environment, and our collaboration with SK pharmteco adds essential manufacturing strength to help NIH advance promising gene therapies for patients in need.” · This partnership highlights SK pharmteco’s ability to serve as a strong technical partner for both emerging biotech firms and large-scale public institutions. It also reflects SK pharmteco’s broader efforts to support rare disease innovators through partnership models designed to help advance complex programs into the clinic. "Collaborating with the NIH and Axle Informatics marks an important step in our efforts to support patients with rare diseases,” said John Lee, Global Head of Viral Vector at SK pharmteco. “Rare disease programs often operate under significant development and funding constraints, making reliable technical execution and flexible partnerships especially important. Get daily news updates when you subscribe to GenePool!

The FDA announces a new framework to expedite treatment approvals for rare genetic diseases, allowing for a single clinical trial to cover multiple mutations of the same gene. This initiative aims to enhance access to therapies for children with rare diseases, exemplified by the successful treatment of KJ Muldoon with a customized gene-editing therapy.